Latest News

Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma.

Apr

02

2025

Senhwa Biosciences Recognized by European Media as One of Taiwan’s Most Noteworthy Biotech Companies in 2025

Mar

07

2025

Senhwa Biosciences Attended Cathay Securities' Institutional Investor Conference to Update the Company's Business Operations and Future Outlook

Dec

26

2024

Senhwa Biosciences announces first patient dosed in the Phase I/II study of Silmitasertib in children and young adults with relapsed refractory solid tumors

Nov

06

2024

Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director 　

Nov

01

2024

Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Neuroblastoma

Oct

25

2024

US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the US National Cancer Institute

Oct

14

2024

Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI

Sep

18

2024